CorMedix (CRMD) director awarded 30,453 restricted stock units

Rhea-AI Filing Summary

CorMedix Inc. director Steven W. Lefkowitz reported receiving 30,453 shares of common stock on January 26, 2026 as restricted stock units granted at $0.00 per share. These units each represent one share of common stock and will vest in full on January 26, 2027, subject to his continued service.

After this grant, he beneficially owns 125,951 shares directly. He also has indirect beneficial ownership of 30,152 shares through the Wade Capital Corporation Money Purchase Plan, where he has voting and investment control, and 2,000 shares held by his spouse.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Lefkowitz Steven W

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	30,453	$0.00	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 125,951 shares (Direct); Common Stock — 30,152 shares (Indirect, Wade Capital Corporation Money Purchase Plan)

Footnotes (1)

1. These shares represent restricted stock units issued on January 26, 2026. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units will vest in full on January 26, 2027, subject to continued service on the vesting date. The Reporting Person beneficially owns these securities through Wade Capital Corporation Money Purchase Plan (an entity for which the Reporting Person has voting and investment control).

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lefkowitz Steven W

(Last) (First) (Middle)

C/O CORMEDIX INC.

389 INTERPACE PKWY, SUITE 450

(Street)

PARSIPPANY NJ 07054

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		A		30,453	A	$0.00(1)	125,951	D
Common Stock								30,152	I(2)	Wade Capital Corporation Money Purchase Plan
Common Stock								2,000	I	Reporting Person's Wife

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units issued on January 26, 2026. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units will vest in full on January 26, 2027, subject to continued service on the vesting date.

2. The Reporting Person beneficially owns these securities through Wade Capital Corporation Money Purchase Plan (an entity for which the Reporting Person has voting and investment control).

	/s/ Beth Zelnick Kaufman, attorney-in-fact	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CorMedix Inc. (CRMD) report for Steven W. Lefkowitz?

CorMedix director Steven W. Lefkowitz reported a grant of 30,453 restricted stock units on January 26, 2026. Each unit represents one share of common stock, granted at $0.00 per share, vesting in full on January 26, 2027, subject to continued service.

How many CorMedix (CRMD) shares does Steven W. Lefkowitz own after this Form 4 filing?

Following the reported grant, Steven W. Lefkowitz directly owns 125,951 CorMedix common shares. He also has indirect beneficial ownership of 30,152 shares via the Wade Capital Corporation Money Purchase Plan and 2,000 additional shares held by his spouse.

What are the vesting terms of the 30,453 restricted stock units at CorMedix (CRMD)?

The 30,453 restricted stock units granted to Steven W. Lefkowitz vest in full on January 26, 2027. Vesting is conditioned on his continued service through that vesting date, after which each unit converts into one share of CorMedix common stock.

How does Steven W. Lefkowitz hold indirect CorMedix (CRMD) share ownership?

Steven W. Lefkowitz beneficially owns 30,152 CorMedix shares through the Wade Capital Corporation Money Purchase Plan. The filing notes he has voting and investment control over this entity, which gives him beneficial ownership of those plan-held shares.

Does the CorMedix (CRMD) Form 4 show any insider share sales by Steven W. Lefkowitz?

The Form 4 reports an acquisition of 30,453 restricted stock units at $0.00 per share, not a sale. It lists his updated direct and indirect beneficial holdings but does not disclose any dispositions of CorMedix common stock in this filing.

What role does Steven W. Lefkowitz hold at CorMedix (CRMD) in this Form 4?

The Form 4 identifies Steven W. Lefkowitz as a director of CorMedix Inc. This status explains why he must report equity grants and holdings, including restricted stock units and indirect ownership through related entities and his spouse, under Section 16 rules.